Everest Medicines Acquires China Rights to LENZ Therapeutics' VIZZ® for Up To $85M Plus Royalties
LENZ is trading near its 52-week low of $6.61 (4.5% above the low).
Summary
LENZ Therapeutics announced a significant partnership with Everest Medicines, granting rights to develop and commercialize its presbyopia treatment, VIZZ (LNZ100), in Greater China. LENZ is eligible to receive up to $85 million in remaining regulatory and sales milestones, alongside tiered mid single-digit to low double-digit royalties on net sales. This deal expands the market for LENZ's FDA-approved product into a major new region, providing a substantial potential revenue stream for the company, which has a market cap of approximately $220 million. The New Drug Application for LNZ100 in China was submitted in September 2025, with regulatory approval anticipated in Q1 2027. This partnership could materially improve LENZ's financial outlook and support its cash runway, especially given recent reported losses from commercialization investments.
At the time of this announcement, LENZ was trading at $6.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $219.8M. The 52-week trading range was $6.61 to $50.40. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.